Risk of Osteoarthritis in an Incident Cohort of People With Psoriatic Arthritis: A Population-based Cohort Study

Objective. To determine the risk of a diagnosis of osteoarthritis (OA) in patients with psoriatic arthritis (PsA) compared to patients with psoriasis and a general population cohort. Methods. Incident PsA patients aged 18–89 years at diagnosis were identified from the United Kingdom Clinical Practice Research Datalink between 1998 and 2014. All patients with PsA were matched to 2 cohorts of patients, both at a 1:4 ratio. The first cohort included patients with psoriasis (and no PsA) and the second was a general population cohort (with no psoriasis or PsA). The baseline prevalence of OA was calculated for each study cohort. The incidence of OA was calculated, and adjusted relative risks (RRadj) were calculated using conditional Poisson regression. Results. We identified 6783 incident PsA patients. The baseline prevalence of OA ranged from 22.1% (95% CI 21.1–23.1) in the PsA cohort to 12.6% (95% CI 12.2–13.0) and 11.0% (95% CI 10.6–11.3) in the psoriasis and general population cohorts, respectively. The incidence of OA was significantly higher in the PsA cohort compared to the psoriasis and general population cohorts after adjusting for BMI (RRadj 1.68, 95% CI 1.46–1.93, and RRadj 1.86, 95% CI 1.62–2.14, respectively). Conclusion. An increased risk of OA was observed in patients with PsA compared to patients with psoriasis alone and those in the general population. Further work is needed to determine whether this reflects a true increase in OA risk or misdiagnosed PsA, and the extent to which it can be explained by differences in the opportunity for OA diagnosis between cohorts.

[1]  C. Coupland,et al.  Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD). , 2020, Osteoarthritis and cartilage.

[2]  A. Ogdie,et al.  Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States , 2020, BMC Rheumatology.

[3]  P. Dagnelie,et al.  Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. , 2019, Diabetes research and clinical practice.

[4]  A. Silman,et al.  Validation of hip osteoarthritis diagnosis recording in the UK Clinical Practice Research Datalink , 2018, Pharmacoepidemiology and drug safety.

[5]  G. Shaddick,et al.  Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study , 2018, Rheumatology.

[6]  G. Shaddick,et al.  Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis , 2018, The British journal of dermatology.

[7]  G. Shaddick,et al.  Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort , 2017, Rheumatology.

[8]  Gavin Shaddick,et al.  Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study , 2017, Annals of the rheumatic diseases.

[9]  F. Blyth,et al.  Population trends in the incidence and initial management of osteoarthritis: age-period-cohort analysis of the Clinical Practice Research Datalink, 1992–2013 , 2017, Rheumatology.

[10]  Matthew L. Thomas,et al.  Effect of anti‐TNF and conventional synthetic disease‐modifying anti‐rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis , 2016, Rheumatology.

[11]  A. Ogdie,et al.  The Epidemiology of Psoriatic Arthritis. , 2015, Rheumatic diseases clinics of North America.

[12]  K. Jordan,et al.  Annual consultation incidence of osteoarthritis estimated from population-based health care data in England , 2015, Rheumatology.

[13]  K. Bhaskaran,et al.  Data Resource Profile: Clinical Practice Research Datalink (CPRD) , 2015, International journal of epidemiology.

[14]  A. Ogdie,et al.  Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network , 2014, Pharmacoepidemiology and drug safety.

[15]  C. Cooper,et al.  Epidemiology and burden of osteoarthritis. , 2013, British medical bulletin.

[16]  D. Margolis,et al.  Validity of The Health Improvement Network (THIN) for the study of psoriasis , 2011, The British journal of dermatology.

[17]  J. Jordan,et al.  Epidemiology of osteoarthritis. , 2010, Clinics in geriatric medicine.

[18]  C. Cavill,et al.  A modified sharp score demonstrates disease progression in established psoriatic arthritis , 2010, Arthritis care & research.

[19]  M. Dougados,et al.  Self-reported prevalence of psoriasis and evaluation of the impact on the natural history of hip osteoarthritis: results of a 10 years follow-up study of 507 patients (ECHODIAH study). , 2009, Joint, bone, spine : revue du rhumatisme.

[20]  S. Bierma-Zeinstra,et al.  Osteoarthritis , 2006, The Lancet.

[21]  D. Gladman,et al.  Psoriatic Arthritis. , 2017, The New England journal of medicine.

[22]  A. Tan,et al.  Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. , 2015, Rheumatology.

[23]  W. Eyler,et al.  PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.